The Norwegian Immunotherapy in Multiple Myeloma Study

Launched by ST. OLAVS HOSPITAL · Feb 26, 2025

Keywords

ClinConnect Summary

The Norwegian Immunotherapy in Multiple Myeloma Study is a research project looking at new treatments for multiple myeloma and related conditions, such as plasma cell leukemia and AL amyloidosis. The main goal is to understand how effective these new immunotherapies are in everyday medical care and to identify any complications that might arise from their use. By gathering this information, the study aims to improve future treatments and create better guidelines for monitoring side effects, ultimately helping to increase survival rates and enhance the quality of life for patients.

If you're an adult aged 18 or older and have been diagnosed with one of these conditions, you may be eligible to participate in this study. Participants will receive one of the new treatments, which are currently not part of clinical trials, such as Teclistamab or Elranatamab, among others. This study is still recruiting participants, and there are no specific exclusions, meaning almost anyone meeting the age and diagnosis criteria can join. As a participant, you can expect to contribute valuable information that will help shape future cancer care and potentially improve outcomes for yourself and other patients.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Participants age ≥ 18 years
• • Prior diagnosis of one of the following
• • Multiple myeloma as defined according to IMWG criteria
• • Primary plasma cell leukemia as defined according to IMWG consensus definition
• • AL-amyloidosis as defined according to IMWG criteria
• * Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):
• • Teclistamab (Tecvayli)
• • Elranatamab (Elrexfio)
• • Talquetamab (Talvey)
• • Idecabtagene vicleucel (ide-cel/Abecma)
• • Ciltacabtagene autoleucel (cilta-cel/Carvykti)
• Exclusion Criteria:
• • None